Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 48.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 139.00 | |
50 mg | In stock | $ 226.00 | |
100 mg | In stock | $ 337.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro. |
Targets&IC50 | TrkA:0.85 nM, MET (Y1230C):0.37 nM, MET (Y1230C):1.2 nM, TrkC:0.85 nM, MET (D1228N):1.3 nM |
Synonyms | DCC-2701 |
Molecular Weight | 510.46 |
Formula | C26H21F3N4O4 |
CAS No. | 1345847-93-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (88.15 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Altiratinib 1345847-93-9 Angiogenesis Tyrosine Kinase/Adaptors c-Met/HGFR Tie-2 FLT Trk receptor VEGFR Cluster of differentiation antigen 135 Trk Receptor Inhibitor CD135 DCC-2701 inhibit FLT3 Vascular endothelial growth factor receptor Tropomyosin related kinase receptor DCC 2701 DCC2701 Fms like tyrosine kinase 3 inhibitor